Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...

It's not looking too good for the biotech.

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) reports positive clinical proof of concept for REC-4881 in familial adenomatous polyposis. The company records milestone progress across its collaborations ...

Recursion is hosting about 60 investors and analysts at its headquarters in Utah. It has generated tons of data with AI and robots, aiming to find a better way to make drugs. Recursion, which has four ...

Recursion Pharmaceuticals presents a compelling investment opportunity due to its AI-driven drug discovery platform, solid financials, and diverse pipeline, setting it apart from competitors like ...

Management expressed confidence in achieving further milestones in 2025, supported by partnerships with Roche and Sanofi. CEO Gibson noted that the partnership milestones generated $45 million in cash ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...

Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...